MarketMoodz
Lilly Loses Share in India's GLP-1 Market as Generics Flood; Novo Holds Firm
Eli Lilly’s grip on India’s GLP-1 weight-loss market weakened in March, sliding to 56% market share from 61% in February as cheap Indian copies hit the scene. Novo Nordisk remained steady at 25% even as price cuts and intense competition reshaped pricing dynamics.
Key Takeaways
- Lilly’s India GLP-1 market share fell to 56% in March from 61% in February.
- 13 Indian generic drugmakers launched 26 semaglutide brands after patent expiry.
- Novo Nordisk’s market share stayed at 25% in March amid price pressure.
- Novo Nordisk cut Ozempic by 38% and Wegovy by 48% on March 31.
- Mounjaro in India is about 13,800 rupees per month, while generics start lower and Novo semaglutide products begin at 5,660 rupees.
People Involved
- Vishal Manchanda Systematix Group Analyst
- Anant Kharad Anand Rathi Analyst
- Rajiv Kovil Diabetologist
- Vikrant Shrotriya Novo Nordisk India Executive
Entities Involved
- Eli Lilly and Company (Lilly) GLP-1 weight-loss drug maker
- Novo Nordisk A/S Manufacturer of Ozempic, Wegovy, and semaglutide products
- Sun Pharmaceutical Industries Ltd Indian generics manufacturer
- Torrent Pharmaceuticals Ltd Indian generics manufacturer
- Dr. Reddy's Laboratories Ltd Indian generics manufacturer
- Zydus Lifesciences Ltd Indian generics manufacturer
MarketMoodz Analysis
From an investor perspective, price erosion in India could compress Lilly and Novo Nordisk’s margins and influence global revenue trajectories. The combination of a patent expiry-driven generics flood and price cuts narrows the pricing power that has supported GLP-1 franchises in other markets, potentially dragging down margins if the trend spreads.
Historically, India’s generics market has acted as a price pressure valve that can alter global pricing expectations. With roughly 100 million Indians living with diabetes and a sizable share of the population overweight, India remains a testing ground for generics-led competition. Analysts expect a small group of players to dominate (Sun Pharma, Torrent, Dr. Reddy’s, Zydus Lifesciences among them), which could set regional benchmarks for pricing and access.
What to watch next: regulatory signals on importation and pricing, any re-pricing by Lilly and Novo Nordisk in other low- and middle-income markets, and potential manufacturing capacity expansions to sustain thin-margin competition if generics remain price-competitive.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial